Better Health for All.
Companies that promote public health and avoid harmful products.
This dimension assesses whether companies contribute to or undermine public health. We track pharmaceutical litigation (opioid cases, drug pricing lawsuits), food safety violations, tobacco and alcohol marketing practices, and NGO reports on community health impacts from industrial operations. Companies selling harmful products while marketing them as safe are penalised heavily.
What we measure
Net health effect of principal goods or services
Revenue share from products with established negative health outcomes
User harm frequency and severity (injuries, recalls, adverse events)
Price accessibility of health products relative to median income
Equitable access for low-income or marginalised populations
Transparency and honesty of health risk disclosures
Addiction mitigation efforts and recovery support
Clinical trial ethics and pharmaceutical patent flexibility
Why it matters
Health-related litigation has produced some of the largest corporate settlements in history — from Big Tobacco to the opioid crisis. Companies that knowingly harm public health face existential legal risk. ESG ratings based on self-reported health and safety metrics miss the lawsuits and investigations that reveal systemic problems before they become headline news.
Company rankings
Search for any company to see their better health for all score
Search CompaniesHow does your portfolio score on better health for all?
Upload your portfolio and find out in seconds.
Audit My PortfolioExplore other values
Rankings based on AI-generated analysis of publicly available data. Not financial advice. See our Risk Disclosure for full details.